Screener
Xeris Biopharma Holdings, Inc. XERS Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$31.1M-1,513% | $2.23M+124% | $11.08M+317% | $621K+104% | -$1.93M+87.2% | ||
| $323K-0.6% | $337K+7.0% | $335K+7.0% | $338K+10.1% | $325K+15.7% | ||
| $11.07M+121% | $4.14M-6.8% | $5.27M+46.6% | $7.64M+12.9% | $5.01M+18.3% | ||
| $8.26M+4,440% | $9.87M+198% | $20.04M— | $18.43M+322% | $182K+102% | ||
| -$209K+25.1% | -$325K-2,400% | -$333K-103% | -$71K— | -$279K— | ||
| —— | -$8.84M-182% | —— | $13.85M— | —— | ||
| $10M+1,083% | $708K+105% | $19.44M+56.9% | $32.21M+2,011% | $845K+117% |
FAQ
- How much cash does Xeris Biopharma Holdings, Inc. generate?
- Xeris Biopharma Holdings, Inc. (XERS) generated $56.6M in operating cash flow over the trailing twelve months.
- Where does Xeris Biopharma Holdings, Inc.'s cash flow data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
